Dermapharm Holding SE posts strong results for Q3 2024, Arkopharma (France) back above prior-year EBITDA levels for first time Consolidated revenue up 2.7% to EUR 890.1 million. Growth in high-margin ...
Out-of-home posters using the term “HER2.0” showed that the drug could also be used to fight gastrointestinal cancers.
Murphy said Marra’s “breadth of global brand commercialization and pharmaceutical product expertise will give Havas Health a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback